BR112012002413A2 - preparação farmacêutica administrável oralmente contendo insulina - Google Patents
preparação farmacêutica administrável oralmente contendo insulinaInfo
- Publication number
- BR112012002413A2 BR112012002413A2 BR112012002413A BR112012002413A BR112012002413A2 BR 112012002413 A2 BR112012002413 A2 BR 112012002413A2 BR 112012002413 A BR112012002413 A BR 112012002413A BR 112012002413 A BR112012002413 A BR 112012002413A BR 112012002413 A2 BR112012002413 A2 BR 112012002413A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical preparation
- orally administrable
- preparation containing
- administrable pharmaceutical
- containing insulin
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 5
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 5
- 102000004877 Insulin Human genes 0.000 title abstract 2
- 108090001061 Insulin Proteins 0.000 title abstract 2
- 229940125396 insulin Drugs 0.000 title abstract 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0900482A HUP0900482A2 (en) | 2009-08-03 | 2009-08-03 | Pharmaceutical formulation for oral administration |
| PCT/IB2010/053499 WO2011015984A1 (en) | 2009-08-03 | 2010-08-02 | Orally administerable pharmaceutical preparation containing insulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012002413A2 true BR112012002413A2 (pt) | 2016-03-01 |
Family
ID=89989155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012002413A BR112012002413A2 (pt) | 2009-08-03 | 2010-08-02 | preparação farmacêutica administrável oralmente contendo insulina |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120129769A1 (enExample) |
| EP (1) | EP2461820A1 (enExample) |
| JP (1) | JP2013501043A (enExample) |
| KR (1) | KR20120088660A (enExample) |
| CN (1) | CN102791282A (enExample) |
| AU (1) | AU2010280418B2 (enExample) |
| BR (1) | BR112012002413A2 (enExample) |
| CA (1) | CA2769620A1 (enExample) |
| HU (1) | HUP0900482A2 (enExample) |
| IL (1) | IL217856A0 (enExample) |
| MX (1) | MX2012001461A (enExample) |
| RU (1) | RU2012109006A (enExample) |
| UA (1) | UA106506C2 (enExample) |
| WO (1) | WO2011015984A1 (enExample) |
| ZA (1) | ZA201201519B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3653224A1 (en) * | 2011-06-29 | 2020-05-20 | Rani Therapeutics, LLC | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| CN111065749B (zh) * | 2017-06-28 | 2024-06-28 | 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） | 用于确定发展1型糖尿病的风险的方法 |
| KR20240171428A (ko) | 2023-05-30 | 2024-12-09 | (주)네오비젼 | 당뇨병 치료를 위한 약물 방출 제어가 가능한 약물 전달용 콘택트렌즈 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3172814A (en) | 1962-04-06 | 1965-03-09 | Jr Edgar A Ferguson | Oral blood sugar lowering compositions |
| JPS5428807A (en) | 1977-08-09 | 1979-03-03 | Hiroyuki Sumi | Oral insulin |
| IL68769A (en) * | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
| ES2045276T3 (es) | 1988-07-21 | 1994-01-16 | Hoffmann La Roche | Preparacion de insulina |
| ATE134875T1 (de) | 1991-12-05 | 1996-03-15 | Alfatec Pharma Gmbh | Perorale applikationsform für peptidarzneistoffe, insbesondere insulin |
| JP3047948B2 (ja) * | 1992-12-07 | 2000-06-05 | 株式会社ツムラ | ペプチド類経鼻投与用組成物 |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5968899A (en) * | 1994-06-03 | 1999-10-19 | Tsumura & Co. | Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption |
| US5461031A (en) * | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| US5653987A (en) | 1995-05-16 | 1997-08-05 | Modi; Pankaj | Liquid formulations for proteinic pharmaceuticals |
| US5970193A (en) | 1996-10-24 | 1999-10-19 | Nortel Networks Corporation | Data communications structures relating to data shelf configurations |
| AU727053B2 (en) | 1997-04-02 | 2000-11-30 | Purdue Research Foundation | Method for oral delivery of proteins |
| WO2000033866A1 (en) | 1998-12-04 | 2000-06-15 | Provalis Uk Limited | Pharmaceutical compositions containing insulin |
| US6375975B1 (en) | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
| MXPA05009493A (es) | 2003-03-04 | 2006-08-11 | Ttdc Bio L P | Composicion de insulina oral y metodos para producirla y utilizarla. |
| JP5103748B2 (ja) * | 2005-02-16 | 2012-12-19 | 東レ株式会社 | 医薬組成物 |
| ES2670856T3 (es) * | 2005-09-06 | 2018-06-01 | Oramed Pharmaceuticals Inc. | Métodos y composiciones para la administración oral de proteínas |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| CN101062408B (zh) * | 2006-04-27 | 2010-12-08 | 深圳市隆阳生物科技有限公司 | 口服胰岛素复合制剂及其制备方法 |
| JP2008266179A (ja) * | 2007-04-19 | 2008-11-06 | Fujifilm Corp | 経肺用組成物 |
| EP2514406A1 (en) * | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| CN102123697B (zh) * | 2008-08-18 | 2015-06-10 | 安特拉贝欧有限公司 | 用于口服给予蛋白质的方法和组合物 |
-
2009
- 2009-08-03 HU HU0900482A patent/HUP0900482A2/hu unknown
-
2010
- 2010-08-02 AU AU2010280418A patent/AU2010280418B2/en not_active Expired - Fee Related
- 2010-08-02 EP EP10757272A patent/EP2461820A1/en not_active Withdrawn
- 2010-08-02 MX MX2012001461A patent/MX2012001461A/es not_active Application Discontinuation
- 2010-08-02 RU RU2012109006/15A patent/RU2012109006A/ru unknown
- 2010-08-02 JP JP2012523416A patent/JP2013501043A/ja active Pending
- 2010-08-02 CA CA2769620A patent/CA2769620A1/en not_active Abandoned
- 2010-08-02 UA UAA201202346A patent/UA106506C2/uk unknown
- 2010-08-02 US US13/387,212 patent/US20120129769A1/en not_active Abandoned
- 2010-08-02 WO PCT/IB2010/053499 patent/WO2011015984A1/en not_active Ceased
- 2010-08-02 KR KR1020127005524A patent/KR20120088660A/ko not_active Withdrawn
- 2010-08-02 CN CN201080038764XA patent/CN102791282A/zh active Pending
- 2010-08-02 BR BR112012002413A patent/BR112012002413A2/pt not_active IP Right Cessation
-
2012
- 2012-01-31 IL IL217856A patent/IL217856A0/en unknown
- 2012-02-29 ZA ZA2012/01519A patent/ZA201201519B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2461820A1 (en) | 2012-06-13 |
| ZA201201519B (en) | 2013-05-29 |
| HUP0900482A2 (en) | 2011-03-28 |
| AU2010280418B2 (en) | 2015-04-09 |
| IL217856A0 (en) | 2012-03-29 |
| HU0900482D0 (en) | 2009-10-28 |
| UA106506C2 (uk) | 2014-09-10 |
| WO2011015984A1 (en) | 2011-02-10 |
| US20120129769A1 (en) | 2012-05-24 |
| JP2013501043A (ja) | 2013-01-10 |
| CA2769620A1 (en) | 2011-02-10 |
| CN102791282A (zh) | 2012-11-21 |
| KR20120088660A (ko) | 2012-08-08 |
| RU2012109006A (ru) | 2013-09-10 |
| AU2010280418A1 (en) | 2012-03-22 |
| MX2012001461A (es) | 2012-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015004734A2 (pt) | proteínas de fusão para tratar uma síndrome metabólica | |
| ECSP14030742A (es) | Proteínas del factor 21 de crecimiento del fibroblasto | |
| BR112014018306A8 (pt) | Miméticos de apelina sintéticos para o tratamento de insuficiência cardíaca | |
| ECSP14013285A (es) | Variantes del factor 21 del crecimiento de fibroblastos | |
| BR112014006684A2 (pt) | análogos de glucagon | |
| BR112013031268A2 (pt) | "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição". | |
| BR112014030966A2 (pt) | composto, composição farmacêutica, e, métodos para inibir serina protease, para inibir tripsina e enteropeptidase, para tratar hiperglicemia, para profilaxia ou tratamento da diabetes, para melhorar a sensibilidade à insulina e para profilaxia ou tratamento da obesidade, hiperlipidemia, uma complicação diabética ou síndrome metabólica | |
| ECSP19025350A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| BR112013021236A8 (pt) | composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença | |
| DOP2011000045A (es) | Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| BR112012022211A2 (pt) | composto. composição farmacêutica, método de tratamento de uma doença meidada por h4r, método de inibição de h4h, método de tratamento da dor ou inflamação resultante de cirurgia de catarata, método para atingir um efeito em um paciente e uso de uma composto | |
| MX2012007806A (es) | Composiciones farmaceuticas para administracion oral de peptidos de insulina. | |
| EA201100910A1 (ru) | Лечение воспалительных заболеваний кишечника бета-дефенсинами млекопитающих | |
| BRPI0916442A2 (pt) | dosagem terapêutica de uma neuregulina ou de uma subsequência da mesma para tratamento ou profilaxia de insuficiência cardíaca | |
| BR112012022552A8 (pt) | uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos | |
| BR112012009432A2 (pt) | anticorpo anti-hsv | |
| BR112012015202A2 (pt) | "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes". | |
| BR112012015977A2 (pt) | composto derivado de poli (ácido lático), método para preparar o composto derivado de poli (ácido lático), complexo do composto de derivado de poli (ácido lático), composição de liberação prolongada de droga, e, método para preparar a composição de liberação prolongada de droga | |
| BR112013019416A2 (pt) | dimaleato de 9-[4-(3-cloro-2-flúor-fenilamino)-7-metóxi-quinazolin-6ilóxi]-1,4-diaza-espiro[5.5]undecan-5-ona, seu uso como medicamento e sua produção | |
| BR112013026680A2 (pt) | composto, método de tratamento de uma doença inflamatória e composição farmacêutica | |
| BR112018010200A2 (pt) | suplemento alimentar, uso do suplemento alimentar, composição alimentar, e aminoácidos | |
| ATE443722T1 (de) | Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung | |
| BR112012002413A2 (pt) | preparação farmacêutica administrável oralmente contendo insulina | |
| BRPI0512503A (pt) | composição que compreende ácido lático e lactoferrina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |